Krystal Biotech (KRYS) saw its KRYS analyst rating maintained at Buy while Jefferies raised the price target to $371 from $310 on February 17, 2026. This action keeps the stock in Buy territory but signals stronger near-term upside from Jefferies.
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
MLARD.PA stock jumps with 50x volume to €170 on EURONEXT; Meyka model projects €255, 50.21% upside
Explore the Reconvilier incident’s impact on Swiss security and economic stability, focusing on local measures and business effects.
The recent release of Epstein files intensifies scrutiny on Andrew Mountbatten-Windsor, featuring new connections with Jeffrey Epstein and Ghislaine.
RAJRAYON.NS stock saw a large volume spike (831,016) on 02 Jan 2026 at close. We analyse price action, fundamentals, Meyka AI grade and a model-based
PU11.F stock fell 41.67% to €0.0035 on XETRA on 21 Jan 2026. We review valuation, risks, Meyka AI grade and price targets for investors.
Intraday: M8H.DE stock falls 96.74% to €0.037 on XETRA. We examine liquidity, valuation and a model forecast